10-Q: Regenerative Medical Group Reports Q3 Loss Amidst Debt

Regenerative Medical Technology Group Inc. reported increased revenue but a significantly higher net loss for Q3 2025, driven by rising interest expenses and debt extinguishment losses, while facing substantial doubt about its ability to continue as a going concern.

Summary

• Revenue for the three months ended September 30, 2025, increased by 19.69% to $1,180,534 compared to $986,308 in the same period of 2024.
• Revenue for the nine months ended September 30, 2025, increased by 35.88% to $3,528,393 compared to $2,596,671 in the same period of 2024.
• Gross profit for Q3 2025 decreased by 32.86% to $501,557, while for the nine months, it increased by 10.22% to $2,031,283.
• Net loss for Q3 2025 significantly widened to $(4,353,741) from $(887,146) in Q3 2024, a 390.76% increase.
• Net loss for the nine months ended September 30, 2025, increased by 30.35% to $(6,419,566) from $(4,924,785) in the prior year.
• Interest expense for Q3 2025 surged by 285.50% to $(3,490,962), and for the nine months, it increased by 17.70% to $(5,440,183).
• The company recorded a loss on extinguishment of debt of $(416,155) in Q3 and for the nine months ended September 30, 2025.
• Operating activities used $744,715 in cash for the nine months ended September 30, 2025, a shift from providing $471,306 in the prior year.
• The company has an accumulated deficit of $73,972,668 and a working capital deficit of $15,762,714 as of September 30, 2025, raising substantial doubt about its ability to continue as a going concern.
• Several promissory notes totaling $1,027,910 in principal are in default, with accrued interest of $1,152,917.
• Disclosure controls and procedures were deemed not effective due to material weaknesses, including lack of written documentation, inadequate communication, and failure to use full purchase accounting for an acquisition.

Sentiment

Score: 2

Explanation: While the company reported revenue growth and outlined ambitious strategic expansion plans, the substantial increase in net loss, surging interest expenses, negative operating cash flow, significant accumulated and working capital deficits, and multiple defaulted loans paint a dire financial picture. The explicit "going concern" doubt and material weaknesses in internal controls indicate severe operational and financial instability, outweighing any positive growth initiatives.

Positives

• Revenue increased by 19.69% for the three months and 35.88% for the nine months ended September 30, 2025, driven by marketing efforts and the Cancun facility.
• Patient procedures revenue significantly increased by $643,815 (76.81%) for the nine months ended September 30, 2025, reaching $1,481,997.
• Training revenue increased by $258,052 (64.38%) for the nine months ended September 30, 2025, reaching $658,844.
• Product supplies revenue increased by $142,645 (11.54%) for the nine months ended September 30, 2025, reaching $1,379,117.
• Successful financing activities provided $1,100,000 in cash for the nine months ended September 30, 2025.
• Strategic outlook includes confirmed plans for four new clinic locations in Indonesia, Puerto Rico, Santiago (Chile), and Lisbon (Portugal).
• Cancun manufacturing facility achieved regulatory approval in 2024 and is transitioning to full-scale production in 2025, with a soft opening of the Advanced Cell Therapy Manufacturing Lab in September 2025.
• Introduction of a new line of innovative Cellgenic peptides in August 2024, expected to increase future revenue.
• Extension agreements for several senior secured promissory notes to July 31, 2026, providing temporary relief from immediate repayment demands.

Negatives

• Net loss for the three months ended September 30, 2025, increased by 390.76% to $(4,353,741) compared to $(887,146) in the prior year.
• Net loss for the nine months ended September 30, 2025, increased by 30.35% to $(6,419,566) compared to $(4,924,785) in the prior year.
• Gross profit for the three months ended September 30, 2025, decreased by 32.86% to $501,557, primarily due to a 183.80% increase in cost of revenue.
• Interest expense for the three months ended September 30, 2025, surged by 285.50% to $(3,490,962), and for the nine months, increased by 17.70% to $(5,440,183).
• Operating activities used $744,715 in cash for the nine months ended September 30, 2025, a significant deterioration from providing $471,306 in the prior year.
• Accumulated deficit reached $73,972,668 and working capital deficit was $15,762,714 as of September 30, 2025.
• Several promissory notes totaling $1,027,910 in principal and $1,152,917 in accrued interest are currently in default.
• The company has insufficient cash to operate its business at the current level for the next twelve months and to repay defaulted notes.
• Disclosure controls and procedures were deemed not effective due to material weaknesses, including lack of written documentation, inadequate communication, and improper accounting for an acquisition.
• The opening of the Dubai clinic was delayed from September 2025 to Spring 2026.
• Equipment sales revenue significantly decreased by $112,790 (93.04%) for the nine months ended September 30, 2025.

Risks

• Risks related to outstanding secured and unsecured loans, certain of which are in default, and the ability to service debt.
• Risk of failure to obtain adequate financing on a timely basis and on acceptable terms to continue as a going concern.
• Uncertainty of profitability based upon a history of losses.
• Legislative or regulatory changes concerning regenerative medicine and therapies.
• Risks related to operations and uncertainties related to the business plan and business strategy.
• Changes in economic conditions.
• Uncertainty with respect to intellectual property rights, protecting those rights, and claims of infringement of others' intellectual property.
• Competition in the regenerative medicine industry.
• Cybersecurity concerns.
• Risk that lenders will call defaulted notes, secure assets, and demand payment, potentially leading to the company going out of business.
• Inability to generate sufficient revenues and/or additional financing to fund expenditures or other cash requirements.
• Material weaknesses in internal control over financial reporting, including lack of written documentation, inadequate communication between personnel, and failure to use full purchase accounting for the GSCG acquisition.

Future Outlook

The company anticipates accelerating revenue growth in future quarters due to ongoing marketing, brand awareness campaigns, training seminars, and the expansion of its presence in the industry. Revenues are expected to increase with the opening of a new clinic in Dubai, UAE (now projected for Spring 2026), and the introduction of new regenerative products like Cellgenic peptides. The operational strategy for 2025 focuses on clinic network expansion (Indonesia, Puerto Rico, Santiago, Lisbon confirmed), manufacturing scale-up at the Cancun facility, and market penetration in key regions including Southeast Asia, Latin America, and potentially North America. The company plans to enhance its educational programs through ISSCA, strengthen partnerships with global medical institutions, and strategically enter new geographic markets, particularly North America, as regulatory environments evolve. Continued investment in R&D is a strategic priority, focusing on exosome characterization, combination therapy protocols, tissue-specific regeneration, biomarker identification, and delivery system innovations. The company aims to balance growth investments with improving profitability metrics through disciplined capital allocation, operational cost control, and strategic acquisitions.

Management Comments

• "We believe stem cell therapy is becoming an increasingly effective clinical solution for treating conditions that traditional or conventional medicine only offers within palliative care and pain management."
• "Our strategy allows us the ability to create immediate revenue streams through treatments, product sales, distribution, and clinical applications, driven by our extensive education platform."
• "We expect that our revenues will increase in future quarters as a result of our ongoing marketing and brand awareness campaigns, training seminars, lectures and other efforts we engage in that expand our presence in the industry and provide us with more opportunities to sell our products."
• "We also expect revenues to increase with the opening of our new clinic in Dubai, UAE, in 2025 [now Spring 2026]."
• "We are pleased to announce that Cellgenic will host a soft opening of our new Advanced Cell Therapy Manufacturing Lab in Cancun during the September 2025 ISSCA Global Summit."
• "Our approach to the U.S. market is characterized by strategic patience combined with proactive preparation."
• "We expect to continue to experience high interest payments in the future as a result of our outstanding liabilities. If we are unable to generate sufficient revenues and/or additional financing to service this debt, there is a risk the lenders will call the notes, and we will be unable to repay the loans. If this happens, we could go out of business."
• "While management believes the risk of acceleration is low based on historical lender forbearance, a formal demand on any defaulted note could trigger acceleration of up to $16.6 million in secured debt."
• "Based upon the current financial condition, we do not have sufficient cash to operate our business at the current level for the next twelve months."

Industry Context

The company operates in the rapidly evolving regenerative medicine industry, focusing on stem cell therapy, exosomes, and peptides. This sector is characterized by significant scientific advancements and increasing patient demand for alternative treatments to conventional medicine. The company's strategy of combining clinical research, product manufacturing, and physician training through its Global Stem Cells Group and ISSCA network aligns with the industry trend of integrated solutions. Its expansion into new geographic markets like Southeast Asia, the Middle East, and Latin America, along with a cautious approach to the U.S. market due to regulatory complexities, reflects the global nature and varying regulatory landscapes of regenerative medicine. The emphasis on product line diversification, including new peptide offerings, indicates a response to broader market opportunities within the therapeutic space.

Corporate Governance

Related Party Transactions

• Dave Christensen, current Director, President, Chief Executive Officer, Chief Financial Officer and Secretary, was compensated $67,500 for consulting services through Enterprise Technology Consulting (a company he owns 100%) for the nine months ended September 30, 2025.
• Benito Novas's brother, sister, and nephew provided marketing/administrative and training/R&D services to Global Stem Cells Group and were paid an aggregate of $208,834 as consultants during the nine months ended September 30, 2025.

Stakeholder Impact

• Shareholders face significant dilution risk due to the issuance of warrants with debt extensions and potential future equity raises. The increased accumulated deficit and going concern doubt pose a high risk to investment value.
• Creditors are at high risk due to several promissory notes being in default and the company's insufficient cash to repay them, potentially leading to non-payment or asset seizure if lenders demand acceleration.
• Employees may experience job insecurity and uncertainty regarding future compensation due to the company's going concern doubt and financial instability.
• Customers and patients could benefit from the expansion of clinics and product lines, but the company's financial instability could pose risks to service continuity or product availability.
• Suppliers may face risks regarding timely payments or the company's ability to fulfill contractual obligations due to its financial difficulties and potential for going out of business.

Next Steps

• Implement remedial actions to address material weaknesses in internal control over financial reporting during the fiscal year ended December 31, 2025.
• Continue marketing and brand awareness campaigns, training seminars, and lectures to expand industry presence and increase product sales.
• Proceed with the official launch of new clinic locations in Indonesia, Puerto Rico, Santiago (Chile), and Lisbon (Portugal).
• Achieve full operational scaling of the Cancun manufacturing facility in 2025.
• Open the new clinic in Dubai, UAE, in Spring 2026.
• Strengthen the Celgenic product line with new offerings in peptides, exosome therapies, and biologics, including new Peptide Pens.
• Enhance global distribution infrastructure.
• Expand educational programming through ISSCA, including increasing training events and physician certifications, deploying an online learning platform, and hosting a major international congress.
• Cultivate relationships with U.S. medical institutions and develop compliant protocols for potential U.S. market entry.
• Seek additional funding through debt and/or equity markets, potentially via a private equity offering.
• Engage in debt restructuring talks for defaulted promissory notes.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by a substantial increase in net losses, surging interest expenses, negative operating cash flow, and a significant working capital deficit. The explicit "going concern" warning, coupled with multiple defaulted loans and insufficient cash to operate for the next twelve months, indicates a high probability of financial collapse or significant restructuring that would severely dilute existing shareholders. Material weaknesses in internal controls further compound the risk. Despite some revenue growth and strategic expansion plans, the fundamental financial health is critically compromised, making the stock a high-risk investment with significant downside potential.

Keywords

Regenerative Medicine, Stem Cell Therapy, Biologics, Exosomes, Peptides, Medical Technology, Clinical Network, SEC Filing, 10-Q, Financial Report, Biotechnology, Healthcare, Global Stem Cells Group, RMTG